Antonio Chella
Azienda Ospedaliera Universitaria Pisana · 226 works · 9,812 citations · h-index 47
Top works
- EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
- Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- BRONCHIOLOALVEOLAR LUNG CARCINOMAS: K-ras MUTATIONS ARE CONSTANT EVENTS IN THE MUCINOUS SUBTYPE
- A pilot study of the role of TC-99 radionuclide in localization of pulmonary nodular lesions for thoracoscopic resection✩
- Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features
- Association between cigarette smoking and FHIT gene alterations in lung cancer.
- Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients
- Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung
- Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
- Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity in the FHIT locus
- Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
- Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (Stage IIIA-N2): Impact of adjuvant therapies in a subset of patients at high risk of recurrence
- Resection of single brain metastasis in non-small-cell lung cancer: Prognostic factors
- Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non–Small-Cell Lung Cancer: Results of a Phase II-III Study
- Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients.
- Crizotinib in MET -Deregulated or ROS1 -Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial